IDEAYA Biosciences $201 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a public offering by IDEAYA Biosciences, Inc. of 8,858,121 shares of common stock at $18.50 per share and pre-funded warrants to purchase 2,020,270 shares of common stock at $18.4999 per pre-funded warrant, which included 1,418,920 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of approximately $201 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”
Based in South San Francisco, California, IDEAYA is a clinical-stage synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Rong (Fiona) Huang. The tax team included partner Kara L. Mungovan and associate William Liang. The intellectual property team included partner David R. Bauer and associate S. Dream Montgomery. Members of the Davis Polk team are based in the Northern California and New York offices.